<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene E484A literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.E484A</span> literature reference collection</h1>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Highly resistant to mAbs SARS2-01, 1B07, SARS2-32, SARS2-35 and SARS2-07 of 10 antibodies tested, and moderately high resistance to the remaining.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.<br/> (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> No effective neutralization in all 4 out of the 4 sera tested.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested.<br/>Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance. (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> "E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels" (<a href="https://doi.org/10.1101/2020.11.30.405472" class="lit_link">Starr et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody (<a href="https://doi.org/10.1016/j.chom.2020.11.007" class="lit_link">Greaney et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab) (<a href="https://doi.org/10.1101/2021.02.17.431683" class="lit_link">Starr et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.<br/> (<a href="https://doi.org/10.1101/2021.04.27.440939" class="lit_link">Engelhart et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
